Study shows how the microbiome shapes lung cancer immunotherapy outcomes
Despite the revolutionary impact of immune checkpoint inhibitors on cancer therapy, 60% to 80% of patients with NSCLC still show suboptimal responses.
9 Sep 17:20 · News-Medical